News Release

  • June 26, 2018 NEWS Our website has just opened.
  • January 12, 2017 PRODUCTS HSC-BANKER GMP grade has become available for sale.
  • July 6, 2016 PRODUCTS A Drug Master File for STEM-CELLBANKER DMSO free GMP grade has been registered.

Overview

ZENOAQ RESOURCE CO., LTD. is an affiliate of NIPPON ZENYAKU KOGYO CO., LTD. (ZENOAQ). In 2014, we commenced an exclusive supply of ‘’CELLBANKER’’ brand of cells and tissues cryopreservation manufactured at ZENOAQ to global market. Since then, we continue to develop advanced life science technologies as well as cryopreservation.

Life science technology has rapidly evolved in recent years, contributing to innovations across a variety of fields and greatly influencing our daily lives. In medicine, it’s significant contribution to the development of novel pharmaceuticals and medical devices have been made, and further advancements are anticipated. In particular, biotechnology that adopts the principles of the diversity of living organisms has a great potential to shape the future of medicine through various applications.

We encourage scientific innovation, and put into practice the biotechnology and related skills to develop products and services for customers.

With our efforts, we strive to provide solutions to improve quality of life of patients, to support healthy and fulfilling lives for many people, and to ensure that all the animals contributing to them can lead valuable lives. We are committed to the medicine, as well as health and welfare of the society.

Research and Development

  • Therapeutic
    Antibodies
  • Vaccine
    Adjuvants
  • Products in Regenerative Medicine
    Cell Cryopreservation Media
  • Therapeutic antibodies provide excellent performance as they are effective against diseases that are resistant to conventional pharmaceuticals. Furthermore, they are associated with a lower risk of side effects since they are highly specific to their targets. Therapeutic antibodies have been developed for various diseases such as inflammatory diseases (e.g. rheumatoid arthritis) and cancer. Currently, almost half of the top 50 pharmaceuticals available on the market are therapeutic antibodies.

    With recent innovations in antibody modification techniques, the number of therapeutic antibodies in a variety of shapes will undoubtedly increase in the near future. The function of the antibody that serves as the basic component has the greatest impact in determining whether development of a therapeutic antibody is successful. However, it can be challenging to obtain a high-quality antibody that can be used for that purpose, and a manufactured antibody should have a high affinity and functionality to be further developed into a therapeutic antibody. Furthermore, there may be additional challenges with antibodies with low target or disease specificity, as they may cause side effects and other problems.

    We are developing a technical platform to efficiently produce high-quality antibodies including disease-specific antibodies and antibodies that are otherwise difficult to create. Using this platform in the process of drug discovery and development of other products and services, we will contribute to the development of pharmaceuticals and diagnostics.

    Antibody

  • The history of vaccines dates back to the end of 18th century when Edward Jenner discovered the smallpox vaccine. Since then, various vaccines have been developed to prevent infections, and these efforts have contributed to the field of medicine.

    Recent studies have revealed the complexity of the immune system in the human body. Given that immune dysregulation causes various diseases, researchers have been making efforts to expand the application of vaccines in medicine. However, there has been little success in the development of novel vaccines. Although various immunologic adjuvants that enhance the ability of vaccines are currently being developed, adjuvants that have been used in practice have not been entirely successful in terms of improving the efficacy and safety of vaccines.

    We developed polymeric microparticles that enhance the function of a vaccine to activate the immune system. The polymer effectively enhances both humoral immunity and cell-mediated immunity. Using the polymer as the basic component, we are developing highly functional adjuvants to develop vaccines with high efficacy and better safety profile. Furthermore, we are applying this technique for other products and services to propose novel therapeutic concepts.

    Adjuvant

  • CELLBANKER is a series of cell cryopreservation media and has been our leading product since it became commercially available in 1991. The medium achieves over 80% cell viability after thawing for most cell lines, and occupies over 70% of the share in experimental reagents in Japan. At present, we are developing novel applications of the CELLBANKER series to meet the needs of current research trends. In particular, the discovery of induced pluripotent stem cells (iPS cells) and related research efforts in recent years are leading the field of regenerative medicine as a novel industry to realize practical applications.

    Regenerative medicine has opened new avenues for curing patients with difficult-to-treat diseases and diseases that are resistant to conventional therapies.

    We are transforming the CELLBANKER series from being experimental in nature to being applicable in regenerative medicine in terms of quality and functionality, as well as addressing current issues with cryopreservation in basic research and clinical settings.

    Cellbanker

Our Products

CELLBANKERSERIES

CELLBANKER 1

  • 100ml
  • 20ml
Reference
Serum contained
[ Feature ]
CELLBANKER 1 enables rapid freezing in a deep freezer without adjusting reagents, thus saving time and effort. It achieves high cell viability after thawing.
More details.

CELLBANKER 1plus

  • 100ml
  • 20ml
Reference
Available only in Japan
Reduced serum contained
[ Feature ]
CELLBANKER 1plus is a modified product of CELLBANKER 1. The new mixing ratio achieves lower viscosity and less bubble formation during pipetting, thus enhancing operability. It achieves high cell viability after thawing.
More details.

CELLBANKER 2

  • 100ml
  • 20ml
Reference
Serum-free
[ Feature ]
CELLBANKER 2 is a serum-free cell cryopreservation medium. Its efficacy is equivalent to media that contain serum. Since it does not contain proteins such as serum and albumin, there is no contamination or effect on cells from these proteins.
More details.

STEM-CELLBANKER
GMP grade

  • 100ml
  • 20ml
Reference
Serum-free
[ Feature ]
Manufacturing and quality control processes for this product are performed under GMP conditions. STEM-CELLBANKER GMP grade is a cryopreservation medium for cells and tissues, and is optimized for storage of valuable cells such as ES cells, iPS cells, and mesenchymal stem cells.
More details.

STEM-CELLBANKER
DMSO Free GMP grade

  • 100ml
  • 20ml
Reference
Serum-free
[ Feature ]
STEM-CELLBANKER DMSO Free GMP grade is a chemically defined (all components are known and chemically defined) and optimized cell cryopreservation medium. Its serum meets the criteria for being xeno-free, meaning it does not contain any animal-derived components. Its components meet the official specifications of the Japanese, United States, and European Pharmacopeia.
More details.

CELLOTION

  • 100ml
Reference
Cell washing and recovery
[ Feature ]
CELLOTION is a chemically defined (all components are known and chemically defined) cell washing and recovery solution. By reducing the loss of cells after washing, it achieves a high cell recovery yield. It is free of serum, protein, and sugars, and is thus suitable for washing cells, tissues, and organs.
More details.

HSC-BANKER
GMP grade

  • 15ml
Reference
Glass vial
Serum-free
[ Feature ]
HSC-BANKER GMP grade is a ready-to-use cryopreservation medium for hematopoietic stem cells. It is entirely made in Japan, and its manufacturing and quality control processes are performed under GMP conditions. To ensure that it is sterility, all manufacturing processes in which the product is exposed to the environment are conducted in a Grade A environment. It is suited for storage of stem cells derived from the umbilical cord.
More details.

Corporate Profile

Corporate Name: ZENOAQ RESOURCE CO., LTD.
Office: 1-1 Tairanoue, Sasagawa, Asaka-machi, Koriyama, Fukushima 963-0196, Japan
Representative: Kuniaki Fukui
Date of Establishment: April 1985
Capital: 100 million yen
Core Business: Research, development, manufacturing, and sales of products and services relating to life science field.
Affiliate: NIPPON ZENYAKU KOGYO CO., LTD. (ZENOAQ)